Morgan Stanley double downgraded CervoMed (CRVO) to Underweight from Overweight without a price target saying multiple questions remain for ...
CervoMed (CRVO) announced topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for the treatment of patients with dementia with Lewy bodies. DLB. The trial did not meet ...
Roth MKM lowered the firm’s price target on CervoMed (CRVO) to $4 from $45 and keeps a Buy rating on the shares. The company has reported ...
Netflix has revealed some more first looks and a new English-language name for its new Italian action drama series, Public Disorder. It was previously developed under the name A.C.A.B. La Series, ...